Código QR

Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1

Inhibition of checkpoint kinase 1 (Chk1) has shown to overcome resistance to poly (ADP-ribose) polymerase (PARP) inhibitors and expand the clinical utility of PARP inhibitors in a broad range of human cancers. Pristimerin, a naturally occurring pentacyclic triterpenoid, has been the focus of intensi...

Descrición completa

Gardado en:
Principais autores: Li Tao, Xiangyu Xia, Shujing Kong, Tingye Wang, Fangtian Fan, Weimin Wang
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2024-03-01
Series:Pharmacological Research
Assuntos:
PARP inhibitor
Pristimerin
Chk1
P53-deficient
Sensitization
Acceso en liña:http://www.sciencedirect.com/science/article/pii/S1043661824000355
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares